CYTEK BIOSCIENCES, INC.

(CTKB)
  Report
Delayed Nasdaq  -  05/19 04:00:00 pm EDT
9.820 USD   +1.76%
05/16Piper Sandler Adjusts Price Target on Cytek Biosciences to $12 From $17, Reiterates Overweight Rating
MT
05/12Morgan Stanley Lowers Price Target for Cytek Biosciences to $11 From $18, Maintains Equalweight Rating
MT
05/12INSIDER SELL : Cytek Biosciences
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cytek Biosciences : Morgan Stanley Starts Cytek Biosciences at Equal-Weight With $26 Price Target

08/17/2021 | 08:10am EDT


© MT Newswires 2021
All news about CYTEK BIOSCIENCES, INC.
05/16Piper Sandler Adjusts Price Target on Cytek Biosciences to $12 From $17, Reiterates Ove..
MT
05/12Morgan Stanley Lowers Price Target for Cytek Biosciences to $11 From $18, Maintains Equ..
MT
05/12INSIDER SELL : Cytek Biosciences
MT
05/12Goldman Sachs Lowers Cytek Biosciences Price Target to $12 From $14, Buy Rating Maintai..
MT
05/12CYTEK BIOSCIENCES, INC. Management's Discussion and Analysis of Financial Condition an..
AQ
05/11Cytek Biosciences Posts Flat Adjusted EPS, Higher Revenue for Q1; Sees 2022 Revenue at ..
MT
05/11Cytek Biosciences Seeks M&A
CI
05/11TRANSCRIPT : Cytek Biosciences, Inc., Q1 2022 Earnings Call, May 11, 2022
CI
05/11Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 EPS $0.01, vs. Street Est of $0.02
MT
05/11Earnings Flash (CTKB) CYTEK BIOSCIENCES Reports Q1 Revenue $35.1M, vs. Street Est of $3..
MT
More news
Analyst Recommendations on CYTEK BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 242 M - -
Net income 2022 1,98 M - -
Net cash 2022 366 M - -
P/E ratio 2022 589x
Yield 2022 -
Capitalization 1 319 M 1 319 M -
EV / Sales 2022 3,95x
EV / Sales 2023 4,40x
Nbr of Employees 511
Free-Float 82,5%
Chart CYTEK BIOSCIENCES, INC.
Duration : Period :
Cytek Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CYTEK BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 9,82 $
Average target price 11,67 $
Spread / Average Target 18,8%
EPS Revisions
Managers and Directors
Wen Bin Jiang President, Chief Executive Officer & Director
Patrik Sebastian Jeanmonod Chief Financial Officer
Ming Yan Director & Chief Technology Officer
Melik Ulusu VP-Operations & Integrated Supply Chain
Jack T. Ball Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CYTEK BIOSCIENCES, INC.-39.83%1 319
THERMO FISHER SCIENTIFIC-18.74%215 594
DANAHER CORPORATION-24.22%178 480
INTUITIVE SURGICAL, INC.-39.29%78 303
SIEMENS HEALTHINEERS AG-17.17%64 740
EDWARDS LIFESCIENCES CORPORATION-27.16%58 675